Oncología clínica y molecular

Adrian SG, Olmos VP, Martinez del Prado P, Martin AJM. Which events to consider in the study of venous thromboses in pancreatic cancer patients? Authors' reply. Eur J Intern Med. 2023. DOI:10.1016/j.ejim.2023.01.013.

Carrera S, Rodriguez Martinez AB, Garin I, Sarasola E, Martinez C, Maortua H, et al. Germline heterozygous exons 8-11 pathogenic BARD1 gene deletion reported for the first time in a family with suspicion of a hereditary colorectal cancer syndrome: more than an incidental finding?. Hered Cancer Clin Pract. 2023; 21(1): 2-2. DOI:10.1186/s13053-023-00246-4.

Casas A, Ciruelos E, Oliveira M, Saura C, Bellet M, Pernas S, et al. Solti-1903 HOPE: Real-world clinical practice study to assess the impact of using genomic data on the next treatment decision making-choice in patients with locally advanced or metastatic breast cancer in Spain. Cancer Res. 2022; 82(4). DOI:10.1158/1538-7445.SABCS21-OT2-06-01.

Silva Cardenas DC, Pikabea Diaz F, Zumarraga Cuesta A, Lopez Santillan M, Figaredo Berjano C, Loaiza Jaramillo PL, et al. Real-world data: incidence of venous thromboembolism recurrence and bleeding among cancer patients. Thromb Res. 2022; 213: 17-17

Diaz FP, Calvo EG, Zumarraga A, Bejarano CF, Gonzalez M, Santillan ML, et al. Predicting Oncotype DX recurrence scores using clinicopathologic features: Tennessee University Nomogram: An external validation. Ann Oncol. 2022; 33: 233-233. DOI:10.1016/j.annonc.2022.03.258.

Dafni U, Soo RA, Peters S, Tsourti Z, Vervita K, Han JY, et al. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis. Ann Oncol. 2022; 33: 46-47. DOI:10.1016/j.annonc.2022.02.041.

de Juan VC, Dols MC, Rodriguez Abreu D, Carcereny E, Cantero A, Caro RB, et al. Determination of essential biomarkers in lung cancer: A real-world data study in Spain. Ann Oncol. 2022; 33: 50-50. DOI:10.1016/j.annonc.2022.02.048.

Provencio M, Cobo M, Rodriguez Abreu D, Calvo V, Carcereny E, Cantero A, et al. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics. BMC Cancer. 2022; 22(1). DOI:10.1186/s12885-022-09830-8.

Dafni U, Soo RA, Peters S, Tsourti Z, Zygoura P, Vervita K, et al. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis. ESMO Open. 2022; 7(3). DOI:10.1016/j.esmoop.2022.100507.

Gregori JG, Miranda EL, Escriva Romani S, Rodriguez BJ, Novoa SA, Morales LF, et al. Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa). Cancer Res. 2022; 82(4). DOI:10.1158/1538-7445.SABCS21-OT1-12-09.

Law EH, Galve Calvo E, Wockel A, Parikh R, Kurosky SK, Ansquer VD, et al. European treatment patterns and outcomes associated with first-line CDK4/6 inhibition and hormonal therapies assessed in a real-world non-interventional study (EUCHARIS). Cancer Res. 2022; 82(4). DOI:10.1158/1538-7445.SABCS21-OT2-19-04.

Provencio M, Rodriguez Abreu D, Ortega AL, Serrano G, Aguado C, Franco F, et al. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. Transl Lung Cancer Res. 2022; 11(1). DOI:10.21037/tlcr-21-504.

Ulibarri Ochoa A, Ruiz Alegria B, Lopez Vivanco G, Garcia Vivar C, Iraurgi I. Differences in Quality of Life and Emotional Well-being in Breast, Colon, and Lung Cancer Patients During Outpatient Adjuvant Chemotherapy: A Longitudinal Study. Cancer Nurs. 2022. DOI:10.1097/NCC.0000000000001070.

Casarrubios M, Cruz Bermudez A, Sierra Rodero B, Nadal E, Molla M, Campelo MRG, et al. Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy. Ann Oncol. 2022; 33: 105-105. DOI:10.1016/j.annonc.2022.02.189.

Provencio M, Serna Blasco R, Nadal E, Insa A, Garcia Campelo MR, Casal Rubio J, et al. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). J Clin Oncol. 2022; 40(25): 2102660-2102660. DOI:10.1200/JCO.21.02660.

Jimenez Labaig P, Mane JM, Rivero MP, Lombardero L, Sancho A, Lopez Vivanco G. Just an Acute Pulmonary Edema? Paraneoplastic Thyroid Storm Due to Invasive Mole. Case Rep Oncol. 2022; 15(2): 566-572. DOI:10.1159/000524467.

Arietaleanizbeaskoa MS, Pablo S, Sancho A, Martin X, Moreno C, Grandes G. Barriers and facilitators of the EfiKroniK exercise program for people with chronic diseases in Primary Care. Aten Primaria. 2022; 54(10). DOI:10.1016/j.aprim.2022.102456.

Aguado de la Rosa C, Cruz Castellanos P, Lazaro Quintela M, Domine M, Vazquez Estevez S, Lopez Vivanco G, et al. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study). Lung Cancer. 2022; 173: 83-93. DOI:10.1016/j.lungcan.2022.09.010.

Casarrubios M, Provencio M, Nadal E, Insa A, Del Rosario Garcia Campelo M, Lazaro Quintela M, et al. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. J Immunother Cancer. 2022; 10(9). DOI:10.1136/jitc-2022-005320.

Marcelo I, Urrutia I, Calvo B, Martinez R, Saso L, Castano L, et al. Prevalence of autoimmunity in relatives of patients with type 1 diabetes: Time to the clinical onset of diabetes and associated risk factors. Horm Res Paediatr. 2022; 95(SUPPL 2): 177-178

Casarrubios M, Cruz Bermudez A, Sierra Rodero B, Martinez C, Nadal E, Calvo V, et al. Tumor Bulk-RNA Seq Identifies Patients at High Risk of Progression in Non-complete Pathological Responders from NADIM Trial. J Thorac Oncol. 2022; 17(9): 6-7

Provencio M, Serna R, Nadal E, Larriba JLG, Martinez Marti A, Bernabe R, et al. Progression Free Survival and Overall Survival in NADIM II Study. J Thorac Oncol. 2022; 17(9): 2-3

Romero A, Serna R, Nadal E, Larriba JLG, Martinez Marti A, Bernabe R, et al. Pre-treatment ctDNA Levels Significantly Predicts of OS and PFS in NADIM II Trial. J Thorac Oncol. 2022; 17(9): 63-63

Labaig PJ, Lombardero L, Rivero MP, Lamin FM, Ortega B, Minambres N, et al. The influence of carrying BRCA pathogenic mutations in ovarian cancer and its platinum-sensitivity: 5-year experience of a tertiary center. J Clin Oncol. 2022; 40(16): 17572-17572

Garcia Pelaez J, Barbosa Matos R, Lobo S, Dias A, Garrido L, Castedo S, et al. Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes. Lancet Oncol. 2022; 24(1): 91-106. DOI:10.1016/S1470-2045(22)00643-X.

Albertos P, Duendar G, Schenk P, Carrera S, Cavelius P, Sieberer T, et al. Transcription factor BES1 interacts with HSFA1 to promote heat stress resistance of plants. Embo J. 2022; 41(3). DOI:10.15252/embj.2021108664.

Casas A, Ciruelos E, Oliveira M, Saura C, Bellet M, Pernas S et al. Solti-1903 hope: Real-world clinical practice study to assess the impact of using comprehensive genomic data on the next treatment decision making-choice in patients with locally advanced or metastatic breast cancer in Spain. Cancer Res. 2021; 81(4)

Provencio M, Mazarico Gallego JM, Calles A, Antoñanzas M, Pangua C, Mielgo Rubio X et al. Lung cancer patients with COVID-19 in Spain: GRAVID study. Lung Cancer. 2021; 157: 109-115. DOI:10.1016/j.lungcan.2021.05.014.

Provencio M, Majem M, Guirado M, Massuti B, de Las Penas R, Laura Ortega A et al. Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection. Lung Cancer. 2021; 153: 25-34. DOI:10.1016/j.lungcan.2021.01.005.

Lopez Santillan M, Lopez E, Alvarez Gonzalez P, Martinez G, Arzuaga Mendez J, Ruiz Diaz I et al. Prognostic and therapeutic value of somatic mutations in diffuse large B-cell lymphoma: A systematic review. Crit Rev Oncol Hematol. 2021; 165: 103430-103430. DOI:10.1016/j.critrevonc.2021.103430.

Feliu J, Jorge Fernandez M, Macarulla T, Massuti B, Albero A, Gonzalez JF et al. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study. Cancer Chemother Pharmacol. 2021; 87(4): 543-553. DOI:10.1007/s00280-020-04214-w.

Laza Briviesca R, Cruz Bermudez A, Nadal E, Insa A, Garcia Campelo MR, Huidobro G et al. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. Clin Transl Med. 2021; 11(7): 491-491. DOI:10.1002/ctm2.491.

Provencio M, Serna Blasco R, Nadal E, Insa A, Garcia Campelo MR, Corbacho DP et al. High levels of baseline ctDNA constitute a poor prognostic factor in progression-free survival in patients receiving neo-adjuvant chemo-immunotherapy: Results from NADIM clinical trial. Cancer Res. 2021; 81(13)

Peters S, Pujol J-L, Dafni U, Domine M, Popat S, Reck M et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy - Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Ann Oncol. 2021; 33(1): 67-79. DOI:10.1016/j.annonc.2021.09.011.

Casarrubios M, Cruz Bermudez A, Nadal E, Insa A, Garcia Campelo MR, Lazaro M et al. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. Clin Cancer Res. 2021; 27(21): 5878-5890. DOI:10.1158/1078-0432.CCR-21-1200.

Majem M, Sullivan I, Viteri S, Lopez Vivanco G, Cobo M, Sanchez JM et al. First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met. Eur J Cancer. 2021; 159: 174-181. DOI:10.1016/j.ejca.2021.09.039.

Provencio M, Nadal E, Insa A, Campelo MRG, Pereiro D, Domine M et al. Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study. J Thorac Oncol. 2021; 16(10): 883-883

Romero A, Nadal E, Serna R, Insa A, Campelo MRG, Benito C et al. Pre-Treatment Levels of ctDNA for Long-Term Survival Prediction in Stage IIIA NSCLC Treated With Neoadjuvant Chemo-Immunotherapy. J Thorac Oncol. 2021; 16(10): 883-884

Casarrubios M, Nadal E, Cruz Bermudez A, Insa A, Briviesca RL, Campelo MRG et al. TCR Repertoire Predicts Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemoimmunotherapy from NADIM Trial. J Thorac Oncol. 2021; 16(3): 545-546

Provencio M, Rodriguez Abreu D, Lorduy AC, Serrano GM, Granados A, Aguado C et al. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients (p): SOLID study. J Clin Oncol. 2021; 39(15). DOI:10.1200/JCO.2021.39.15_suppl.8531.

Briviesca RL, Nadal E, Casarrubios M, Insa A, Sierra Rodero B, Campelo MRG et al. Molecular Insight into NADIM Clinical Trial: Potential Immune Biomarkers of Pathological Response for NSCLC Patients. J Thorac Oncol. 2021; 16(3): 220-221

Sierra Rodero B, Cruz Bermudez A, Nadal E, Garitaonaindia Y, Insa A, Mosquera J et al. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. J Immunother Cancer. 2021; 9(8). DOI:10.1136/jitc-2021-002804.

Cruz Bermudez A, Casarrubios M, Briviesca RL, Nadal E, Insa A, Mosquera J et al. TMB and Selected Mutations in Resectable Stage IIIA NSCLC Patients Receiving Neo-Adjuvant Chemo-Immunotherapy from NADIM Trial. J Thorac Oncol. 2021; 16(3): 543-543

Ibarrondo O, Álvarez López I, Freundlich F, Arrospide A, Galve Calvo E, Gutiérrez Toribio M, et al. Probabilistic cost-utility analysis and expected value of perfect information for the Oncotype multigenic test: a discrete event simulation model. Gac Sanit. 2020; 34(1): 61-68. DOI:10.1016/j.gaceta.2018.07.012.

Bermejo de Las Heras B, Cortes Ramon Cajal YJ, Galve Calvo E, de la Haba Rodriguez J, Garcia Mata J, Moreno Anton F, et al. The economic burden of metastatic breast cancer in Spain. Eur J Hosp Pharm. 2020; 27(1): 19-24. DOI:10.1136/ejhpharm-2017-001453.

Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020; 21(5): 645-654. DOI:10.1016/S1470-2045(20)30068-1.

Carbonero RG, Jimenez Fonseca P, Benavent M, Alonso V, Crespo G, Teule A, et al. WHO Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasm (GEP-NEN): Data from 358 Patients of the Spanish Group of Neuroendocrine and Endocrine Tumors Registry (R-GETNE). Neuroendocrinology. 2020; 110: 72-72

del Prado MPM, Vicente BLD, Arteaga J, Folgueira JL, Cuesta AZ, Diaz FP, et al. Oncotype DX assay's real world data in early stage breast cancer patients. Outcomes of a cohort treated in the Basurto University Hospital, Spain. Cancer Res. 2020; 80(4). DOI:10.1158/1538-7445.SABCS19-P3-14-05.

Barquin M, Calvo V, Garcia F, Nunez B, Sanchez Herrero E, Serna Blasco R, et al. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation. Cancer Epidemiol. 2020; 67. DOI:10.1016/j.canep.2020.101737.

Remon J, Nadal E, Domine M, Ruffinelli J, Garcia Y, Pardo JC, et al. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. Lung Cancer. 2020; 147: 83-90. DOI:10.1016/j.lungcan.2020.06.034.

Costa EC, Calvo V, Guirado M, Granados A, Castro RL, Rodriguez Abreu D, et al. Small cell lung cancer (SCLC) extensive stage (ES) in Spain: Efficacy of treatments, data from the thoracic tumours registry (TTR study). Ann Oncol. 2020; 31: 1036-1036. DOI:10.1016/j.annonc.2020.08.1547.

Subbiah V, Paz Ares L, Besse B, Moreno V, Zaman K, Gonzalez M, et al. Activity of lurbinectedin in second-line SCLC patients candidates for platinum re-challenge. Ann Oncol. 2020; 31: 1034-1035. DOI:10.1016/j.annonc.2020.08.1545.

Franco F, Costa EC, Rodriguez Abreu D, Castro RL, Dols MC, Guirado M, et al. Description of the clinical characteristics and survival in patients with metastatic NSCLC in the Spanish population: An analysis of the thoracic tumours registry (RTT study). Ann Oncol. 2020; 31: 879-879. DOI:10.1016/j.annonc.2020.08.1694.

Manso L, Hernando C, Galan M, Oliveira M, Cabrera MA, Bratos R, et al. Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP). Breast. 2020; 54: 286-292. DOI:10.1016/j.breast.2020.11.005.

Garcia Campelo R, Arrieta O, Massuti B, Rodriguez Abreu D, Ortega Granados AL, Majem M, et al. Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Lung Cancer. 2020; 150: 62-69. DOI:10.1016/j.lungcan.2020.09.018.

Subbiah V, Paz Ares L, Besse B, Moreno V, Peters S, Angeles Sala M, et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer. 2020; 150: 90-96. DOI:10.1016/j.lungcan.2020.10.003.

Sánchez Torre M, Sánchez Torre A, Bertran S, Abad J, Duran Cantolla J, Cabriada V, et al. Effect of obstructive sleep apnoea and its treatment with continuous positive airway pressure on the prevalence of cardiovascular events in patients with acute coronary syndrome (ISAACC study): a randomised controlled trial. Lancet Resp Med. 2020; 8(4): 359-367. DOI:10.1016/S2213-2600(19)30271-1.

Bjorck M, Earnshaw JJ, Acosta S, Goncalves FB, Cochennec F, Debus ES, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia. Eur J Vasc Endovasc Surg. 2020; 59(2): 173-218. DOI:10.1016/j.ejvs.2019.09.006.

Garcia Pelaez J, Monteiro AR, Sousa L, Pinheiro H, Castedo S, Garrido L, et al. The first genotype-phenotype study of European carriers of CDH1 germline mutations. Medicine (Baltimore). 2020; 99(9)

Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischaemia (vol 58, pg 1, 2019). Eur J Vasc Endovasc Surg. 2020; 60(1): 158-159. DOI:10.1016/j.ejvs.2020.04.033.

Provencio M, Nadal E, Insa A, Garcia Campelo MR, Casal Rubio J, Domine M, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020; 21(11): 1413-1422. DOI:10.1016/S1470-2045(20)30453-8.

Batlle JF, Fernandez MJ, Macarulla T, Massuti B, Albero A, Gonzalez F, et al. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: BIBABRAX study. J Clin Oncol. 2020; 38(15)

Arietaleanizbeaskoa MS, Sancho A, Olazabal I, Moreno C, Gil E, Garcia Alvarez A, et al. Effectiveness of physical exercise for people with chronic diseases: the EFIKRONIK study protocol for a hybrid, clinical and implementation randomized trial. BMC Fam Pract. 2020; 21(1): 227-227. DOI:10.1186/s12875-020-01298-4.

Peters S, Pujol JL, Dafni U, Domine M, Becker A, Andrade J, et al. Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial. Ann Oncol. 2020; 31: 1211-1211. DOI:10.1016/j.annonc.2020.08.2326.

De Jesus Acosta A, Crespo Herrero G, Gomez Dorronsoro ML, Alonso V, Riesco Martinez MC, Custodio A, et al. SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus. Ann Oncol. 2019; 30(5)

Valderrama BP, Perez Ramirez S, Rodriguez Vida A, Gonzalez del Alba A, Mendez Vidal MJ, Vazquez Estevez S, et al. SPAZO2 (SOGUG): Outcomes and prognostic significance of IMDC intermediate prognosis subclassification in metastatic renal cell carcinoma (mRCC) in patients treated with 1st-line pazopanib (1stPz). Ann Oncol. 2019; 30(5): 385-385

Guirado M, Majem M, Sureda BM, Bataller RD, Granados A, Casado M, et al. NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC). Ann Oncol. 2019; 30: 594-594

Costa EC, Guirado M, Herrero CJC, Barrera JB, Garcia Campelo MR, Granados A, et al. Tobacco use in lung cancer (LC) patients (p) in Spain. Ann Oncol. 2019; 30: 749-749

Abreu DR, Guirado M, Herrero CJC, Barrera JB, Bernabe R, Casal J, et al. Biomarker testing of lung cancer in Spain. Ann Oncol. 2019; 30

Carcereny E, Franco F, Rodriguez Abreu D, Castro RL, De Las Penas R, Guirado M, et al. Smoking Habit in Lung Cancer in Spain. J Thorac Oncol. 2019; 14(10): 784-785. DOI:10.1016/j.jtho.2019.08.1686.

Provencio M, Franco F, Sanchez Hernandez A, Romero ES, Giron CG, Domine M, et al. Liquid Biopsy: Association Between the Burden of Disease in Patients with EGFR-Mutated NSCLC and the Frequency of Its Detection in Blood. J Thorac Oncol. 2019; 14(10): 751-751. DOI:10.1016/j.jtho.2019.08.1609.

Rodriguez Abreu D, Moran T, Castro RL, Guirado M, Camps C, Nunez B, et al. Analysis of Biomarkers in Lung Cancer in Spain. J Thorac Oncol. 2019; 14(10): 752-752. DOI:10.1016/j.jtho.2019.08.1611.

Herrero ES, Franco F, Auglite M, Blasco RS, Del Romo MB, Sanchez Hernandez A, et al. ctDNA Levels Significantly Predicts Survival in NSCLC Patients with an EGFR Activating Mutation. J Thorac Oncol. 2019; 14(10): 696-696. DOI:10.1016/j.jtho.2019.08.1480.

Perez JMT, Subbiah V, Besse B, Moreno V, Lopez R, Sala MA, et al. Antitumor Activity of Single Agent Lurbinectedin in Patients with Relapsed SCLC Occurring >= 30 Days After Last Platinum Dose. J Thorac Oncol. 2019; 14(10): 535-535.

Karachaliou N, Paulina Bracht JW, Fernandez Bruno M, Drozdowskyj A, Capitan AG, Moran T, et al. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2019; 14(2): 304-310. DOI:10.1016/j.jtho.2018.10.168.

Carrera S, Beristain E, Sancho A, Iruarrizaga E, Rivero P, Manuel Mane J, et al. Germline c.1A > C heterozygous pathogenic variant in SDHA reported for the first time in a young adult with a gastric gastrointestinal stromal tumour (GIST): a case report. Hered Cancer Clin Pract. 2019; 17(1): 23-23. DOI:10.1186/s13053-019-0124-6.

Urrutia I, Martinez R, Rica I, Martinez de LaPiscina I, Garcia Castano A, Aguayo A, et al. Negative autoimmunity in a Spanish pediatric cohort suspected of type 1 diabetes, could it be monogenic diabetes?. PLoS One. 2019; 14(7). DOI:10.1371/journal.pone.0220634.

Mendizabal Gallastegui N, Arietaleanizbeascoa Sarabia M, Latorre Garcia PM, Iruarrizaga Ovejas E, Sancho Gutierrez A, Grandes Odriozola G. Physical exercise to improve the quality of life of people in treatment for tumor processes: EFICANCER study. Int J Integr Care. 2019; 19(1). DOI:10.5334/ijic.s3472.

Conde E, Hernandez S, Martinez R, Angulo B, De Castro J, Collazo Lorduy A, et al. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study. J Thorac Oncol. 2019; 14(12): 2120-2132. DOI:10.1016/j.jtho.2019.07.005.

Laza Briviesca R, Cruz Bermudez A, Casarrubios M, Nadal E, Insa Molla MA, Garcia Campelo M-R, et al. Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients. Ann Oncol. 2019; 30(5)

Massuti Sureda B, Sanchez Torres JM, Cobo Dols M, Moran Bueno MT, Gonzalez Larriba JL, Barneto Aranda IC, et al. BRCA1 expression level as prognostic factor for recurrence in resected NSCLC with adjuvant chemotherapy: SCAT Trial. Ann Oncol. 2019; 30(5)

Azkona E, Carrera S, Rubio I, Mane JM, Lacambra I, Sancho A, et al. Influence of Radiotherapy in Second-Line Treatment with Immunotherapy in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol. 2019; 14: 969-969. DOI:10.1016/j.jtho.2019.08.2123.

Laza Briviesca R, Cruz Bermudez A, Casarrubios M, Nadal E, Insa A, Garcia Campelo R, et al. Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients. J Thorac Oncol. 2019; 14: 711-711. DOI:10.1016/j.jtho.2019.08.1515.

Massuti B, Sanchez JM, Cobo M, Moran T, Gonzalez Larriba JL, Barneto I, et al. Reccurrence Pattern After Adjuvant Customized Chemotherapy Based on BRCA Expression Level (SCAT Trial). J Thorac Oncol. 2019; 14: 252-252. DOI:10.1016/j.jtho.2019.08.502.

Provencio M, Nadal E, Insa A, Garcia Campelo R, Casal J, Domine M, et al. NADIM Study: Updated Clinical Research and Outcomes. J Thorac Oncol. 2019; 14: 241-241. DOI:10.1016/j.jtho.2019.08.480.

Laza Briviesca R, Cruz Bermudez A, Barquin M, Nadal E, Insa A, Garcia Campelo R, et al. Haematological biomarkers of pathological response on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA non-small cell lung cancer (NSCLC) patients. J Clin Oncol. 2019; 37

Provencio M, Nadal E, Insa A, Garcia Campelo R, Casal Rubio J, Domine M, et al. Neoadjuvant chemo-immunotherapy for the treatment of stage IIIA resectable non-small-cell lung cancer (NSCLC): A phase II multicenter exploratory study-Final data of patients who underwent surgical assessment. J Clin Oncol. 2019; 37

Arriola E, Paredes Lario A, García Gomez R, Diz Tain P, Constenla M, García Girón C, et al. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS. Clin Transl Oncol. 2018; 20(10): 1261-1267. DOI:10.1007/s12094-018-1855-y.

Callejo Goena A, Rubio Etxebarria I, Sancho Gutiérrez A, Azkuna Sagarduy J, Lopetegi Aizpurua A, López Vivanco G. Infective endocarditis in a patient with metastatic colorectal cancer. Rev Esp Quimioter. 2018; 31(1): 75-77

Garcia Foncillas J, Tabernero J, Elez E, Aranda E, Benavides M, Camps C, et al. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. Br J Cancer. 2018; 119(12): 1464-1470. DOI:10.1038/s41416-018-0293-5.

Conde E, Hernandez S, Martinez R, De Castro J, Collazo Lorduy A, Jimenez B, et al. Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients. J Thorac Oncol. 2018; 13(10): 553-554. DOI:10.1016/j.jtho.2018.08.785.

Provencio M, Nadal E, Insa A, Campelo RG, Huidobro GG, Domine M, et al. Phase II Study of Neo-Adjuvant Chemo/Immunotherapy for Resectable Stages IIIA Non-Small Cell Lung Cancer-Nadim Study-SLCG. J Thorac Oncol. 2018; 13(10): 320-320. DOI:10.1016/j.jtho.2018.08.236.

Redondo A, Vazquez MR, Manso L, Gil MJG, Llinas IG, Garcia Garre E, et al. Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study. OncoTargets Ther. 2018; 11: 5845-5852. DOI:10.2147/OTT.S170303.

de San Vicente BL, Calvo EG, Zumarraga A, Pikabea F, Arteaga J, Santillan ML, et al. Surgery of the primary tumor for de novo metastatic breast cancer: The controversy continues. Ann Oncol. 2018; 29

Gandhi L, Rodriguez Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22): 2078-2092. DOI:10.1056/NEJMoa1801005.

Mane JM, Calvo B, Aresti U, Carrera S, Sancho A, Azkona E, et al. Epithelial ovarian cancer and primary peritoneal carcinomatosis in the elderly: what is our clinical practice?. Eur J Gynaecol Oncol. 2017; 38(5): 695-699. DOI:10.12892/ejgo3674.2017.

de Juan VC, Molla AI, Dols MC, Sureda BM, Lopez Vivanco G, Rubio JC, et al. Neo-adjuvant chemo/immunotherapy for the treatment of resectable stage IIIA non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study" NADIM trial. Ann Oncol. 2017; 28(5)

Gonzalez M, de la Pena FA, Vazquez RM, Garcia Saenz JA, Calvo EG, Manas J, et al. Retrospective observational study to evaluate the use of halaven plus trastuzumab for the treatment of HER2(1) metastatic breast cancer (MBC) in Spain: HALATRUST study. Ann Oncol. 2017; 28(5)

Foncillas JG, Tabernero J, Aguilar EA, Benavides M, Camps CJ, Lopez R, et al. First prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis. Ann Oncol. 2017; 28(5)

Chaib I, Karachaliou N, Pilotto S, Servat JC, Cai XT, Li XF, et al. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. JNCI-J Natl Cancer Inst. 2017; 109(9). DOI:10.1093/jnci/djx014.

Carrera S, Sancho A, Azkona E, Azkuna J, Lopez Vivanco G. Hereditary pancreatic cancer: related syndromes and clinical perspective. Hered Cancer Clin Pract. 2017; 15. DOI:10.1186/s13053-017-0069-6.

Karachaliou N, Gimenez Capitan A, Drozdowskyj A, Aldeguer E, Cao MG, Cardona AF, et al. Expression of genes associated with anti-viral response in EGFR mutant non-small cell lung cancer (NSCLC). Ann Oncol. 2017; 28(2)

Lopez Vivanco G, Salvador J, Diez R, Lopez D, De Salas Cansado M, Navarro B, et al. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain. Clin Transl Oncol. 2017; 19(12): 1454-1461. DOI:10.1007/s12094-017-1684-4.

Karachaliou N, Chaib I, Cardona A, Lopez Vivanco G, Vergnenegre A, Sanchez JM, et al. Co-Activation of STAT3 and YAP1 Signaling Pathways Limits EGFR Inhibitor Response in Lung Cancer. J Thorac Oncol. 2017; 12(1): 1216-1217. DOI:10.1016/j.jtho.2016.11.1714.

Karachaliou N, Morales Espinosa D, Vila M, Garde J, Baron F, Cobo M, et al. AZD9291 as 1st-Line Therapy for EGFR Mutant NSCLC Patients with Concomitant Pretreatment EGFR T790M Mutation. The AZENT Study. J Thorac Oncol. 2017; 12(1): 1074-1075. DOI:10.1016/j.jtho.2016.11.1503.

Vazquez MR, Redondo A, Manso L, Gil M, Garau I, Perez Carrion R, et al. Long-term responders to first-line bevacizumab-based therapy in metastatic breast cancer (MBC) patients: Results of the observational study LORENA. J Clin Oncol. 2017; 35(15). DOI:10.1200/JCO.2017.35.15_suppl.e12563.

Gonzalez Martin A, Alba E, Ciruelos E, Cortes J, Llombart A, Lluch A, et al. Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. Curr Cancer Drug Targets. 2016; 16(5): 415-428. DOI:10.2174/1568009615666150817121731.

Espinosa E, Soriano V, Malvehy J, Berrocal A, Martinez de Prado P, Quindos M, et al. Treatment patterns of adjuvant interferon-alpha 2b for high-risk melanoma: a retrospective study of the Grupo Espanol Multidisciplinar de Melanoma - Prima study. Melanoma Res. 2016; 26(3): 278-283. DOI:10.1097/CMR.0000000000000254.

Camps C, Albanell J, Anton A, Aranda E, Carrato A, Cassinello J, et al. Quality Indicators to Assure and Improve Cancer Care in Spain Using the Delphi Technique. J Natl Compr Cancer Netw. 2016; 14(5): 553-558. DOI:10.6004/jnccn.2016.0063.

Arriola E, Paredes A, Gomez RG, Diz P, Constenla M, Girón CG, et al. 147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study. J Thorac Oncol. 2016; 11(4 Suppl). DOI:10.1016/S1556-0864(16)30257-X.

Cacicedo J, Fernandez I, del Hoyo O, Gomez Iturriaga A, Martinez Indart L, Frias A, et al. Prognostic Value of Maximum Standardized Uptake Value Measured by Pretreatment 18F-FDG PET/CT in Locally Advanced Head and Neck Squamous Cell Carcinoma: Adding Value to Clinical Staging. Int J Radiat Oncol Biol Phys. 2016; 96(2, S): 383-383

Karachaliou N, Chaib I, Cai X, Li X, Cardona AF, Lopez Vivanco G, et al. Poly-therapy with EGFR, STAT3 and Src-YAP1 signaling pathway inhibition; A breakthrough for EGFR mutant NSCLC. Ann Oncol. 2016; 27(6). DOI:10.1093/annonc/mdw382.2.

Sancho A, Carrera S, Arietaleanizbeascoa M, Arce V, Mendizabal Gallastegui N, March AG, et al. Supervised physical exercise to improve the quality of life of cancer patients: the EFICANCER randomised controlled trial. BMC Cancer. 2015; 15(1). DOI:10.1186/s12885-015-1055-x.

Arrospide A, Soto Gordoa M, Acaiturri T, Lopez Vivanco G, Carlos Abecia L, Mar J. Cost of Breast Cancer Treatment by Clinical Stage in the Basque Country, Spain. Rev Esp Salud Publica. 2015; 89(1): 93-97. DOI:10.4321/S1135-57272015000100010.

Karachaliou N, Codony Servat J, Teixido C, Pilotto S, Drozdowskyj A, Codony Servat C, et al. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Sci Rep. 2015; 5. DOI:10.1038/srep17499.

Ayala F, Feijoo M, Martinez N, Florian Gerico J, Gomez A, Sanchez Rovira P, et al. Clinical profile and prognosis of metastatic breast cancer (MBC) patients with long-lasting response to eribulin (E): Results of the EXTER study. J Clin Oncol. 2015; 33(15)

Garcia Campelo R, Moran T, Cardenal F, Alonso Jaudenes Curbera G, Carcereny Costa E, Pallares C, et al. BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p). J Clin Oncol. 2015; 33(15)

Diaz Rubio Garcia E, Anton A, Aranda E, Carrato A, Gascon P, Lopez Vivancos G, et al. Developing standards and indicators for quality improvement for cancer patients in Spain. Eur J Cancer. 2015; 51(3): 156-156

Cacicedo J, Fernandez I, del Hoyo O, Dolado A, Gomez Suarez J, Hortelano E, et al. Should PET/CT be implemented in the routine imaging work-up of locally advanced head and neck squamous cell carcinoma? A prospective analysis. Eur J Nucl Med Mol Imaging. 2015; 42(9): 1378-1389. DOI:10.1007/s00259-015-3071-0.

Massuti B, Cobo M, Manuel Rodriguez Paniagua J, Isabel Ballesteros A, Moran T, Arrabal R, et al. Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial (Eudract:2007-000067-15; NCTgov:00478699). J Clin Oncol. 2015; 33(15)

Capdevila J, Sevilla I, Alonso V, Anton Aparicio L, Jimenez Fonseca P, Grande E, et al. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis. BMC Cancer. 2015; 15. DOI:10.1186/s12885-015-1512-6.

Lopez Vivanco G, Carrera S, Rubio I, Azcona E, Sancho A, Calvo B, et al. Final results of a phase II study of bevacizumab, cisplatin and pemetrexed as first-line therapy for patients with advanced non squamous non small cell lung cancer. J Clin Oncol. 2015; 33(15)

Doval D, Cinieri S, Bozcuk H, Pierga J, Altundag K, Wang X, et al. Exploratory post hoc analyses of patient-reported outcomes (PROs) in the IMELDA randomized phase III trial: Maintenance bevacizumab (BEV) +/- capecitabine (CAP) after initial first-line BEV plus docetaxel (DOC) for HER2-negative metastatic breast can. Cancer Res. 2015; 75(9)

Massuti B, Manuwl Rodriguez Paniagua J, Cobo Dols M, Arrabal R, Ballesteros I, Pun YW, et al. Results Ph III Trial Customized Adjuvant CT after Resection of NSCLC with Lymph Node Metastases SCAT: A Spanish Lung Cancer Group Trial. J Thorac Oncol. 2015; 10(9): 180-180

Carrera S, Buque A, Azkona E, Aresti U, Calvo B, Sancho A, et al. Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies. Clin Transl Oncol. 2014; 16(4): 339-350. DOI:10.1007/s12094-013-1143-9.

Aresti U, Carrera S, Iruarrizaga E, Fuente N, Marrodan I, de Lobera AR, et al. Estrogen Receptor 1 Gene Expression and Its Combination with Estrogen Receptor 2 or Aromatase Expression Predicts Survival in Non-Small Cell Lung Cancer. PLoS One. 2014; 9(10). DOI:10.1371/journal.pone.0109659.

Uribarri M, Hormaeche I, Zalacain R, Lopez Vivanco G, Martinez A, Nagore D, et al. A New Biomarker Panel in Bronchoalveolar Lavage for an Improved Lung Cancer Diagnosis. J Thorac Oncol. 2014; 9(10): 1504-1512. DOI:10.1097/JTO.0000000000000282.

Moran T, Wei J, Cobo M, Qian X, Domine M, Zou Z, et al. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies(aEuro). Ann Oncol. 2014; 25(11): 2147-2155. DOI:10.1093/annonc/mdu389.

Martin Algarra S, Soriano V, Malvehy J, Berrocal A, Quindos M, Martinez Del Prado P, et al. TREATMENT PATTERNS OF ADJUVANT INTERFERON ALFA-2B (IFN-alpha 2B) FOR HIGH-RISK MELANOMA. A RETROSPECTIVE STUDY OF THE GRUPO ESPAnOL MULTIDISCIPLINAR DE MELANOMA (GEM). Ann Oncol. 2014; 25(4)

Cacicedo J, Del Hoyo O, Rodeno E, Fernandez I, Rodriguez O, Dolado A, et al. Utility Of 18F-Fluorodeoxyglucose Positron Emission Tomography (PET/CT) in the Staging and Treatment Plan Evaluation of Head and Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2014; 90(1): 552-552. DOI:10.1016/j.ijrobp.2014.05.1674.

Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014; 15(1): 59-68. DOI:10.1016/S1470-2045(13)70510-2.

Lecumberri R, López Vivanco G, Font A, González Billalabeitia E, Gúrpide A, Gómez Codina J, Isla D, Galán A, Bover I, Domine M, Vicente V, Rosell R, Rocha E. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Resultsfromthe ABEL study. Thromb Res. 2013;132:666-70. FI: 3,133(Q2)

Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHerStudyGroup. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14:962-70. FI: 25,117(Q1)

Castellano D, Garcia del Muro X, Climent MA, Maroto P, Perez-Gracia JL, Lopez-Vivanco G, Zhang K, Fly K, Hariharan S, Anton-Aparicio L. Sunitinib expanded-access trial in metastatic renal cell carcinoma (mRCC) - final results from Spain. Eur  J Cancer.  2013; 49: 666.FI: 5,061(Q1)

Buqué A, Aresti U, Calvo B, ShMuhialdin J, Muñoz A, Carrera S, Azkona E, Rubio I, López-Vivanco G. Thymidylate Synthase Expression Determines Pemetrexed Targets and Resistance Development in Tumour Cells. PLoS One. 2013;8:e63338. FI: 3,730(Q1)

De Cock E, Semiglazov V, Lopez Vivanco G, Verma S, Pivot X, Gligorov J, Hauser N, Urspruch A, Kritikou P, Knoop A. Time savings with trastuzumab subcutaneous vs intravenous administration: a time and motion study. Breast 2013;22: S88.  FI: 1,967(Q2).

E Alba, E Ciruelos, R López, JM López-Vega, A Lluch, M Martín, et al.  Cost–Utility Analysis of NanopA Albumin-Bound Paclitaxel versus Paclitaxel in Monotherapy in Pretreated Metastatic Breast Cancer in Spain. Expert Rev Pharmacoeconomics Outcomes Res 2013;13:381-91.